Rigel Pharmaceuticals price target raised to $3 from $2 at Citi

Citi raised the firm’s price target on Rigel Pharmaceuticals to $3 from $2 and keeps a Buy rating on the shares. There were no major surprises in the Q4 print given the preannouncement in early January, the analyst tells investors in a research note. The firm continues to believe Rezlidhia’s "differentiated" durability profile relative to Tibsovo positions Rigel to eventually become the market share leader.